Counterpoint: Chemosensitivity assays for recurrent ovarian cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 9, Issue 1, 2011, Pages 121-124

  Markman, Maurie ^a  

^a CANCER TREATMENT CENTERS OF AMERICA   (United States)

Author keywords

Chemotherapy; In vitro chemosensitivity testing; Ovarian cancer

Indexed keywords

PLATINUM;

ASSAY; CHEMOSENSITIVITY; DATA ANALYSIS; EVIDENCE BASED PRACTICE; HUMAN; IN VITRO STUDY; MEDICAL RECORD; OVARY CANCER; PREDICTIVE VALUE; PROGNOSIS; RECURRENT DISEASE; REVIEW;

EID: 78951478153     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0010     Document Type: Review

References (19)

1. Salmon SE, Hamburger AW, Soehnlen B, et al. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 1978;298:1321-1327. (Pubitemid 8357629)
2. Von Hoff DD, Clark GM, Stogdill BJ, et al. Prospective clinical trial of a human tumor cloning system. Cancer Res 1983;43:1926-1931.
3. Bertelsen CA, Sondak VK, Mann BD, et al. Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations. Cancer 1984;53:1240-1245.
4. Kern DH, Weisenthal LM. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 1990;2:582-588.
5. Alberts DS, Samon S.E, Chen HS, et al. In-vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet 1980;2:340-342.
6. Von Hoff DD, Kronmal R, Salmon SE, et al. A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer. Cancer 1991;67:20-27.
7. Kurbacher CM, Cree IA, Bruckner HW, et al. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs 1998;9:51-57.
8. Maenpaa JU, Heinonen E, Hinkka SM, et al. The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial. Gynecol Oncol 1995;57:294-298.
9. Loizzi V, Chan JK, Osann K, et al. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 2003;189:1301-1307.
10. Holloway RW, Mehta RS, Finkler NJ, et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol 2002;87:8-16.
11. Nagourney RA, Brewer CA, Radecki S, et al. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. Gynecol Oncol 2003;88:35-39.
12. Gallion H, Christopherson WA, Coleman RL, et al. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 2006;16:194-201.
13. Schrag D, Garewal HS, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 2004;22:3631-3638.
14. Samson DJ, Seidenfeld J, Ziegler K, Aronson N. Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 2004;22:3618-3630.
15. Eltabbakh GH. Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma. J Surg Oncol 2000;73:148-152.
16. Eltabbakh GH, Piver MS, Hempling RE, et al. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Gynecol Oncol 1998;70:392-397.
17. Karam AK, Chiang JW, Fung E, et al. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. Gynecol Oncol 2009;114:246-252.
18. Warren JL, Yabroff KR, Meekins A, et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 2008;100:888-897.
19. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 2009;360:626-633.